@misc{indiciae4e36993a9c2c,
  title = {Adjuvant tislelizumab, lenvatinib, and capecitabine for resected biliary tract cancer: a prospective phase II trial.},
  author = {Yun Feng and Ning Zhang and Yi-Ming Zhao and Qi Pan and An-Rong Mao and Wei-Ping Zhu and Ti Zhang and Lu Wang},
  year = {2026},
  doi = {10.1186/s12916-026-04650-0},
  url = {https://pubmed.ncbi.nlm.nih.gov/41578300/},
  note = {Source identifier: 41578300}
}